AKEBIA THERAPEUTICS, INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
AKEBIA THERAPEUTICS, INC. (AKBA) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $12.81 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-02-26
- AKEBIA THERAPEUTICS, INC. research and development asset acquired other than through business combination, written-off for fiscal 2025 was $12.81M.
- AKEBIA THERAPEUTICS, INC. research and development asset acquired other than through business combination, written-off for fiscal 2024 was $0.00.
- AKEBIA THERAPEUTICS, INC. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|
| 2025-12-31 | $12.81M 10-K · filed 2026-02-26 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |